Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 10/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | PRNP | P04156 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acepromazine SCHEMBL28142113 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL29582179 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL29441481 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL30620438 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL21803694 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL29876174 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL30616039 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL204733 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL7253707 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 | |
| Acepromazine SCHEMBL204734 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ADRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9976 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4654963-A1 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | Annovis Bio, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | claimed |
| US-12427140-B2 | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of pain in an animal | THULIN CLAES (SE) | 2025-09-30 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| WO-1993008801-A1 | PREVENTION OF DRUG-INDUCED AGRANULOCYTOSIS WITH FREE RADICAL SCAVENGERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-05-13 | — | — | WO | claimed |
| WO-1992021347-A1 | IMPROVED EUTHANASIA COMPOSITIONS | MICHIGAN STATE UNIVERSITY (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4249003-A | Process for polycyclic amines | AKTIEBOLAGET LEO (SE) | 1981-02-03 | — | — | US | claimed |
| US-4213981-A | ACEPROMAZINE AND MIDFLUR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-07-22 | — | — | US | claimed |